Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 2Peritoneal Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Sunitinib 19Everolimus 17Bevacizumab 13aldesleukin 11Sorafenib 11Interleukin-2 10Cyclophosphamide 10Axitinib 10Nivolumab 9fludarabine phosphate 7fludarabine 7pembrolizumab 5Gemcitabine 5temsirolimus 4pazopanib 4Ipilimumab 4peginterferon alfa-2b 3durvalumab 3cabozantinib 3Radiosurgery 3Interferon-alpha 3Granulocyte-Macrophage Colony-Stimulating Factor 3Filgrastim 3Erlotinib Hydrochloride 3Cryosurgery 3vandetanib 2spartalizumab 2perflutren 2ixabepilone 2chiron 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Kidney Neoplasms × lentiviral minigene vaccine of COVID-19 coronavirus × Clear all
NCT00085436 2018-06-26

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
18 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡